The twice-yearly shot lenacapavir, sold under the name Yeztugo, reportedly nearly eliminated new HIV infections in studies of ...

As Congress finalizes a sweeping new federal spending bill, healthcare providers are sounding the alarm over what could be at ...

The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts ...

A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug ...

National Aids Commission (NAC) and health campaigners have welcomed the approval of a twice-a-year HIV prevention injection ...

Clinical trials have shown that six-monthly injections of lenacapavir are almost 100 percent protective against becoming ...

Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be HIV-negative to get it.

The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across ...

The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that ...

HIV targets the white blood cells and weakens the immune system. This would make the person prone to diseases like ...

The FDA's approval of lenacapavir, a highly effective HIV prevention drug, sparks debate in India due to its high cost of ₹24 ...